Page last updated: 2024-12-06

sertaconazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sertaconazole is a synthetic antifungal medication used topically to treat fungal infections of the skin. It is a member of the imidazole class of antifungals, which work by inhibiting the synthesis of ergosterol, a vital component of fungal cell membranes. Sertaconazole is effective against a wide range of dermatophytes, yeasts, and molds, including Malassezia globosa, a common cause of dandruff and seborrheic dermatitis. It is available in various formulations, such as creams, lotions, and shampoos. Sertaconazole is generally well-tolerated, but some common side effects include itching, redness, and irritation at the application site. It is often studied to explore its efficacy and safety in treating various fungal infections, particularly those resistant to other antifungal medications.'

sertaconazole : A racemate comprising equimolar amounts of (R)- and (S)-sertaconazole. A broad spectrum antifungal with added antipruritic and anti-inflammatory activity used (as its nitrate salt) for treatment of various skin infections. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole : A member of the class of imidazoles that carries a 2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl group at position 1. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID65863
CHEMBL ID1201196
CHEBI ID83682
CHEBI ID82866
SCHEMBL ID66043
MeSH IDM0169568

Synonyms (77)

Synonym
AC-6939
AB00514018-07
BRD-A95939040-008-03-3
sertaconazole [inn]
(+-)-1-(2,4-dichloro-beta-((7-chlorobenzo(b)thien-3-yl)methoxy)phenethyl)imidazole
7-cloro-3-(1-(2,4-diclorofenil)-2-(1h-imidazol-1-il)etoxi-metil)benzo(b)tiofeno [spanish]
sertaconazolum [latin]
sertaconazol [spanish]
1-(2-((7-chlorobenzo(b)thien-3-yl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-1h-imidazole
1h-imidazole, 1-(2-((7-chlorobenzo(b)thien-3-yl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-
brn 5385663
7-chloro-3-(1-(2,4-dichlorophenyl)-2-(1h-imidazol-1-yl)ethoxy-methyl)benzo(b)thiophene
PRESTWICK3_001045
NCGC00179356-01
1-[2-[(7-chlorobenzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole
99592-32-2
sz
7-chloro-3-[1-(2,4-dichlorophenyl)-2-(1h-imidazol-1-yl)ethoxy-methyl]benzo[b]thiophene
BSPBIO_000970
PRESTWICK2_001045
BPBIO1_001068
AB00514018
sertaconazole
DB01153
PRESTWICK1_001045
PRESTWICK0_001045
SPBIO_002905
D06883
sertaconazole (inn)
HMS2089M16
1-[2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole
7-cloro-3-(1-(2,4-diclorofenil)-2-(1h-imidazol-1-il)etoxi-metil)benzo(b)tiofeno
sertaconazole [inn:ban]
unii-72w71i16eg
72w71i16eg ,
sertaconazolum
sertaconazol
FT-0674560
FT-0674561
demofix
CHEMBL1201196
chebi:83682 ,
FT-0631003
AKOS015850283
sertaconazole [who-dd]
sertaconazole [mi]
sertaconazole [vandf]
DL-208
JLGKQTAYUIMGRK-UHFFFAOYSA-N
SCHEMBL66043
1-[2-[(7-chlorobenzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; nitric acid
1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole
1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}-1h-imidazole
DTXSID0048551 ,
1-(2-((7-chlorobenzo[b]thiophen-3-yl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-1h-imidazole
AB00514018_08
STL452922
bdbm50051842
SR-05000001439-1
FT-0674559
Q3479994
BCP12180
NCGC00179356-09
CS-0009631
HY-B0736
EN300-6481081
Z2194031487
sertaconazolum (latin)
dtxcid6028107
rac-1-(2-((7-chloro-1-benzothiophen-3-yl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-1h-imidazole
(+-)-sertaconazole
(rs)-sertaconazole
rac-sertaconazole
g01af19
d01ac14
racemic sertaconazole
chebi:82866

Research Excerpts

Overview

Sertaconazole is an antifungal cream with anti-inflammatory, antipruritic and antistaphylococcal activity. It is effective and safe for the treatment for superficial mycoses, such as tineas, candidiasis, and pityriasis versicolor.

ExcerptReferenceRelevance
"Sertaconazole nitrate (STZ) is a poorly soluble antifungal drug commonly used for treating fungal skin infections. "( Corneal targeted Sertaconazole nitrate loaded cubosomes: Preparation, statistical optimization, in vitro characterization, ex vivo permeation and in vivo studies.
Abdel-Halim, SA; Elassasy, AI; Younes, NF, 2018
)
2.26
"Sertaconazole is an antifungal cream with anti-inflammatory, antipruritic and antistaphylococcal activity."( Comparison of sertaconazole 2% cream versus hydrocortisone 1% ointment in the treatment of atopic dermatitis.
Alyaseen, S; Jowkar, F; Saki, N, 2013
)
1.47
"Sertaconazole is a broad-spectrum third-generation imidazole derivative that is effective and safe for the treatment for superficial mycoses, such as tineas, candidiasis, and pityriasis versicolor."( The efficacy and safety of sertaconazole cream (2 %) in diaper dermatitis candidiasis.
Bonifaz, A; Graniel, MJ; Mena, C; Ponce-Olivera, RM; Tirado-Sánchez, A; Valencia, A, 2013
)
1.41
"Sertaconazole is a useful antifungal agent against mycoses of the skin and mucosa, such as cutaneous, genital and oral candidiasis and tinea pedis. "( Sertaconazole: an antifungal agent for the topical treatment of superficial candidiasis.
Carrillo-Muñoz, AJ; Eraso, E; Giusiano, G; Jauregizar, N; Marcos-Arias, C; Quindós, G; Tur-Tur, C, 2013
)
3.28
"Sertaconazole nitrate is a broad spectrum imidazole antifungal agent with antibacterial and anti-inflammatory properties. "( Poly(ethylene glycol)-block-poly(ε-caprolactone) nanomicelles for the solubilization and enhancement of antifungal activity of sertaconazole.
Attia, MA; Mohamed, RA; Soliman, GM, 2014
)
2.05
"Sertaconazole is a well established antifungal agent, which is now available in a variety of formulations, and remains a useful treatment option particularly in patients with fungal infections resistant to other azoles."( Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology.
Croxtall, JD; Plosker, GL, 2009
)
2.52
"Sertaconazole is a new antifungal agent. "( Efficacy and tolerability of sertaconazole nitrate 2% cream vs. miconazole in patients with cutaneous dermatophytosis.
Baliga, V; Bolmall, C; Ghosh, S; Kura, M; Rao, GR; Saple, DG; Sharma, A; Surjushe, A, 2011
)
2.1
"Sertaconazole nitrate is a broad-spectrum antifungal agent indicated in the United States for the treatment of tinea pedis interdigitalis. "( Safety and efficacy of sertaconazole nitrate cream 2% in the treatment of tinea pedis interdigitalis: a subgroup analysis.
Bödeker, RH; Borelli, C; Korting, HC; Neumeister, C, 2010
)
2.11
"Sertaconazole is an imidazole-type antifungal agent that has shown considerable in vitro activity against pathogenic fungi. "( Sertaconazole: updated review of a topical antifungal agent.
Carrillo-Muñoz, AJ; Ezkurra, PA; Giusiano, G; Quindós, G, 2005
)
3.21
"Sertaconazole nitrate is an antifungal agent that exhibits anti-inflammatory activity; however, the mechanism for this action was unknown. "( Anti-inflammatory activity of sertaconazole nitrate is mediated via activation of a p38-COX-2-PGE2 pathway.
Babad, JM; Garay, M; Liebel, FT; Southall, MD; Sur, R, 2008
)
2.08
"Sertaconazole is a new topical anti-mycotic with demonstrated efficacy against dermatophyte infections in adults. "( Sertaconazole in the treatment of pediatric patients with cutaneous dermatophyte infections.
Aliaga, A; Casanovas, JM; Clanxet, J; Fajo, G; Losada, I; Van Esso, D; Vilallonga, M,
)
3.02
"Sertaconazole is a new synthetic antifungal which has shown promising activity against numerous fungi. "( Ultrastructural alterations produced by sertaconazole on several opportunistic pathogenic fungi.
Cano, JF; Figueras, MJ; Guarro, J,
)
1.84
"Sertaconazole is a new azolic derivative containing a benzo(b)-thiophene group, for topical use. "( Antifungal activity of sertaconazole in vitro against clinical isolates of Candida spp..
Aller, AI; Martin-Mazuelos, E; Montero, O; Morilla, D,
)
1.88
"Sertaconazole is a pharmaceutical product in the form of a cream, gel, powder and solution for dermatological use and vaginal cream, tablets and ovules for gynecological use. "( Sertaconazole in the treatment of mycoses: from dermatology to gynecology.
Camps, F; Márquez, M; Torres, J, 2000
)
3.19
"Sertaconazole is a broad spectrum antifungal agent with excellent activity against yeasts, dermatophytes and opportunistic fungi. "( Sertaconazole: pharmacology of a gynecological antifungal agent.
Ortiz, JA; Palacín, C; Tarragó, C, 2000
)
3.19

Effects

Sertaconazole has broad-spectrum antifungal activity against dermatophytes of the Trichophyton, Epidermophyton and Microsporum genera. It is effective against opportunistic filamentous fungi and Gram-positive bacteria.

ExcerptReferenceRelevance
"Sertaconazole has a wide action spectrum that includes yeasts and dermatophyte fungi, and it is also active against bacteria, mainly Gram-positive cocci, making it highly efficient in the treatment of polymicrobial infections."( Sertaconazole: updated review of a topical antifungal agent.
Carrillo-Muñoz, AJ; Ezkurra, PA; Giusiano, G; Quindós, G, 2005
)
2.49
"Sertaconazole has shown an anti-inflammatory effect that is very useful for the relief of unpleasant symptoms."( Sertaconazole: an antifungal agent for the topical treatment of superficial candidiasis.
Carrillo-Muñoz, AJ; Eraso, E; Giusiano, G; Jauregizar, N; Marcos-Arias, C; Quindós, G; Tur-Tur, C, 2013
)
2.55
"Sertaconazole has broad-spectrum antifungal activity against dermatophytes of the Trichophyton, Epidermophyton and Microsporum genera, and yeasts of the genera Candida and Cryptococcus; additionally, it is effective against opportunistic filamentous fungi and Gram-positive bacteria."( Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology.
Croxtall, JD; Plosker, GL, 2009
)
2.52
"Sertaconazole has a wide action spectrum that includes yeasts and dermatophyte fungi, and it is also active against bacteria, mainly Gram-positive cocci, making it highly efficient in the treatment of polymicrobial infections."( Sertaconazole: updated review of a topical antifungal agent.
Carrillo-Muñoz, AJ; Ezkurra, PA; Giusiano, G; Quindós, G, 2005
)
2.49

Actions

ExcerptReferenceRelevance
"Sertaconazole did not produce skin irritation nor systemic side effects."( Pharmacokinetics and tolerance of sertaconazole in man after repeated percutaneous administration.
Badenas, JM; Farré, M; Márquez, M; Ortiz, JA; Roset, P; Ugena, B, 1992
)
1.28

Treatment

ExcerptReferenceRelevance
"Treatment with sertaconazole also resulted in the induction of cyclooxygenase-2 (COX-2) and the subsequent release of prostaglandin E2 (PGE2)."( Anti-inflammatory activity of sertaconazole nitrate is mediated via activation of a p38-COX-2-PGE2 pathway.
Babad, JM; Garay, M; Liebel, FT; Southall, MD; Sur, R, 2008
)
0.97

Toxicity

Sertaconazole is a broad-spectrum third-generation imidazole derivative that is effective and safe for the treatment for superficial mycoses, such as tineas, candidiasis, and pityriasis versicolor.

ExcerptReferenceRelevance
" LD50 was indeterminable (greater than 8000 mg/kg) in all routes of dosing."( Acute toxicity studies of sertaconazole.
Grau, MT; Ortiz, JA; Romero, A; Sacristán, A, 1992
)
0.58
" The results, in general, have shown low toxic effects, which can be summarized as a slight non-significant hepatomegalia in the rat with increased gamma-GTP and alkaline phosphatase values and a high urinary pH value; no histopathological changes were observed."( Subacute toxicity and maximum tolerable dose of sertaconazole in repeated administration studies.
Grau, MT; Ortíz, JA; Romero, A; Sacristán, A; Villamayor, F, 1992
)
0.54
" The results obtained show that the toxic effects may be summarized as a smaller body weight increase in rats at 150 and 300 mg/kg and in male ferrets at 250 mg/kg."( Chronic toxicity studies of sertaconazole after oral administration to rats and ferrets.
Grau, MT; Ortiz, JA; Romero, A; Sacristán, A; Villamayor, F, 1992
)
0.58
" Sertaconazole did not present any risk, since the phototoxicity level reached was null, with 2 being the minimum value considered as having toxic significance."( Dermal tolerance and phototoxicity studies of sertaconazole.
Grau, MT; Ortiz, JA; Romero, A; Sacristán, A, 1992
)
1.45
" Tolerance and safety were evaluated by a general blood analysis and interrogation of the patient on adverse effects."( Multi-centre double-blind trial on the efficacy and safety of sertaconazole 2% cream in comparison with miconazole 2% cream on patients suffering from cutaneous mycoses.
Alomar, C; Bassas, S; Casas, M; Crespo, V; Ferrándiz, C; Fonseca, E; Hernández, B; Noguera, J; Pedragosa, R; Peyrí, J, 1992
)
0.52
" No serious adverse events were reported, and rates of cutaneous adverse events were comparable between treatment groups."( The safety and efficacy of sertaconazole nitrate cream 2% for tinea pedis.
Jorizzo, J; Savin, R, 2006
)
0.63
" Secondary end points included reducing signs and symptoms and reporting adverse events (AEs)."( Safety and efficacy of sertaconazole nitrate cream 2% in the treatment of tinea pedis interdigitalis: a subgroup analysis.
Bödeker, RH; Borelli, C; Korting, HC; Neumeister, C, 2010
)
0.67
" Sertaconazole is a broad-spectrum third-generation imidazole derivative that is effective and safe for the treatment for superficial mycoses, such as tineas, candidiasis, and pityriasis versicolor."( The efficacy and safety of sertaconazole cream (2 %) in diaper dermatitis candidiasis.
Bonifaz, A; Graniel, MJ; Mena, C; Ponce-Olivera, RM; Tirado-Sánchez, A; Valencia, A, 2013
)
1.6
" There was side effect (3."( The efficacy and safety of sertaconazole cream (2 %) in diaper dermatitis candidiasis.
Bonifaz, A; Graniel, MJ; Mena, C; Ponce-Olivera, RM; Tirado-Sánchez, A; Valencia, A, 2013
)
0.69
" The levels of satisfaction from treatment and any adverse effects (AEs) were also assessed in both groups."( The efficacy and safety of pimecrolimus 1% cream vs. sertaconazole 2% cream in the treatment of patients with facial seborrhoeic dermatitis: a randomized blinded trial.
Azizzadeh, M; Bagheri, B; Pahlevan, D, 2022
)
0.97

Dosage Studied

ExcerptRelevanceReference
" One useful alternative approach is once-daily dosing of topical antifungal agents rather than the traditional twice-daily regimen, an example of what has been called a "forgiving" regimen, designed to promote patient adherence."( Treatment of interdigital tinea pedis: once-daily therapy with sertaconazole nitrate.
Koestenblatt, EK; Weinberg, JM, 2011
)
0.61
" However, the penetration/permeation study results were largely influenced by experimental setup and dosing regimen."( Comparative efficacy evaluation of different penetration enhancement strategies for dermal delivery of poorly soluble drugs - A case with sertaconazole nitrate.
Bubić Pajić, N; Dobričić, V; Ilić, T; O'Mahony, C; Savić, S; Vucen, S, 2021
)
0.82
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
dichlorobenzeneAny member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.
etherAn organooxygen compound with formula ROR, where R is not hydrogen.
imidazolesA five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
1-benzothiophenes
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Indoleamine 2,3-dioxygenase 1Homo sapiens (human)IC50 (µMol)6.10000.05373.075710.0000AID1184068; AID1718979
CholinesteraseEquus caballus (horse)IC50 (µMol)7.40000.00002.22149.4000AID1718976
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
regulation of activated T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell tolerance inductionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of chronic inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of type 2 immune responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
female pregnancyIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic process to kynurenineIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
response to lipopolysaccharideIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of interleukin-10 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of interleukin-12 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
multicellular organismal response to stressIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
kynurenic acid biosynthetic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
swimming behaviorIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
'de novo' NAD biosynthetic process from tryptophanIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
electron transfer activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
heme bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
indoleamine 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
metal ion bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
cytosolIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
smooth muscle contractile fiberIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
stereocilium bundleIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
cytoplasmIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1184070Inhibition of mouse IDO1 expressed in mouse P815B cells using L-tryptophan substrate incubated for 18 hrs by HPLC based cellular assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1184071Inhibition of mouse TDO expressed in mouse P815B cells using L-tryptophan substrate incubated for 24 hrs by HPLC based cellular assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID1184069Inhibition of IDO1 (unknown origin) using L-tryptophan substrate incubated for 60 mins in presence of 0.01% Triton-X by HPLC2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1184072Cytotoxicity against mouse P815B cells after 24 hrs by MTS/PMS assay2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID717844Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 20 uM after 45 mins by spectrophotometric analysis relative to control2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1718979Inhibition of human N-terminal IDO1 expressed in Escherichia coli BL21 A1 cells using L-tryptophan as substrate measured after 30 mins by HPLC analysis2021Bioorganic & medicinal chemistry letters, 02-15, Volume: 34Novel BuChE-IDO1 inhibitors from sertaconazole: Virtual screening, chemical optimization and molecular modeling studies.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1184075Inhibition of IDO1 (unknown origin) at highest soluble concentration using L-tryptophan substrate incubated for 60 mins by HPLC2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID1184068Inhibition of IDO1 (unknown origin) using L-tryptophan substrate incubated for 60 mins by HPLC2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1184074Solubility of the compound in pH 6.5 phosphate buffer containing 5% DMSO2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID1718976Inhibition of equine serum BuChE using butyrylthiocholine iodide as substrate preincubated for 5 mins followed by substrate addition and measured after 2 mins by Ellman's method2021Bioorganic & medicinal chemistry letters, 02-15, Volume: 34Novel BuChE-IDO1 inhibitors from sertaconazole: Virtual screening, chemical optimization and molecular modeling studies.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (109)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.92)18.7374
1990's31 (28.44)18.2507
2000's31 (28.44)29.6817
2010's32 (29.36)24.3611
2020's14 (12.84)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 81.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index81.04 (24.57)
Research Supply Index5.00 (2.92)
Research Growth Index6.44 (4.65)
Search Engine Demand Index139.82 (26.88)
Search Engine Supply Index2.03 (0.95)

This Compound (81.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials27 (22.31%)5.53%
Reviews7 (5.79%)6.00%
Case Studies6 (4.96%)4.05%
Observational0 (0.00%)0.25%
Other81 (66.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy Of Sertaconazole 2% (ERTACZO) in the Treatment of Interdigital Tinea Pedis With Once a Day Treatment for 4 Weeks [NCT00856596]Phase 330 participants (Anticipated)Interventional2009-03-31Recruiting
Randomisierte, Doppelblinde, Plazebo-kontrollierte Prüfung Zum Nachweis Der Wirksamkeit Und Der Lokalen Verträglichkeit Einer 2%Igen Sertaconazol-Crème Bei Patienten Mit Atopischer Dermatitis (Abridged) [NCT01792713]Phase 270 participants (Actual)Interventional2013-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]